

(19) **DANMARK**

(10) **DK/EP 3628732 T3**



Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **C 12 N 15/10 (2006.01)** **C 12 N 9/00 (2006.01)** **C 12 N 9/22 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2023-05-30**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2023-05-03**
- (86) Europæisk ansøgning nr.: **19187628.3**
- (86) Europæisk indleveringsdag: **2015-11-05**
- (87) Den europæiske ansøgnings publiceringsdag: **2020-04-01**
- (30) Prioritet: **2014-11-05 US 201462075713 P** **2015-10-16 US 201562242935 P**
- (62) Stamansøgningsnr: **15798597.9**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA**
- (72) Opfinder: **GLOECKNER, Christian, Wolfstrasse 10A, 53111 Bonn, Tyskland**
Amirali, Kia, Illumina, 5200 Illumina Way, San Diego, CA 92122, USA
He, Molly, Illumina, 5200 Illumina Way, San Diego, CA 92122, USA
Osothprarop, Trina Faye, Illumina, 5200 Illumina Way, San Diego, CA 92122, USA
Steemers, Frank J, Illumina, 5200 Illumina Way, San Diego, CA 92122, USA
Gunderson, Kevin L, 511 Whisper Wind Drive, Encinitas, CA 92024, USA
AMINI, Sasan, 626 Poplar Avenue, Redwood City, CA 94061, USA
JENDRISAK, Jerome, 726 Post Road, Madison, WI 53713, USA
- (74) Fuldmægtig i Danmark: **Novagraaf Brevets, Bâtiment O2, 2 rue Sarah Bernhardt CS90017, F-92665 Asnières-sur-Seine cedex, Frankrig**
- (54) Benævnelse: **TRANSPOSASESAMMENSÆTNINGER TIL REDUKTION AF INSERTIONSBIAS**
- (56) Fremdragne publikationer:
EP-A1- 2 527 438
EP-A1- 2 712 931
WO-A1-2010/048605
WO-A2-2014/108810
FR-A1- 2 900 935
US-A1- 2010 120 098
SIMONE PICELLI ET AL: "Tn5 transposase and tagmentation procedures for massively scaled sequencing projects", GENOME RESEARCH, vol. 24, no. 12, 30 July 2014 (2014-07-30) , pages 2033-2040, XP055236186, US ISSN: 1088-9051, DOI: 10.1101/gr.177881.114
MARIE-V PRG A(C)RONIQUE DEMATTEI ET AL: "Site-directed integration of transgenes: transposons revisited using DNA-binding-domain technologies", GENETICA ; AN INTERNATIONAL JOURNAL OF GENETICS AND EVOLUTION, KLUWER ACADEMIC PUBLISHERS, DO, vol. 138, no. 5, 7 August 2009 (2009-08-07), pages 531-540, XP019789321, ISSN: 1573-6857

Fortsættes ...

NAUMANN T A ET AL: "Production of combinatorial libraries of fused genes by sequential transposition reactions", **NUCLEIC ACIDS RESEARCH**, OXFORD UNIVERSITY PRESS, GB, vol. 30, no. 21, 1 November 2002 (2002-11-01), pages e119-1, XP002712587, ISSN: 1362-4962, DOI: 10.1093/NAR/GNF118

IWANKA KOZAREWA ET AL: "Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes", **NATURE METHODS**, vol. 6, no. 4, 1 April 2009 (2009-04-01), pages 291-295, XP055087323, ISSN: 1548-7091, DOI: 10.1038/nmeth.1311

DESCRIPTION

BACKGROUND

[0001] Transposase enzymes are useful in *in vitro* transposition systems. They allow for massive-scale fragmentation and tagging of genomic DNA and are useful for making libraries of tagged DNA fragments from target DNA for use in nucleic acid analysis methods such as next-generation sequencing and amplification methods. There remains a need for transposase compositions and tagmentation methods with improved properties and which generate tagged DNA fragments that are qualitatively and quantitatively representative of the target nucleic acids in the sample from which they are generated.

BRIEF SUMMARY

[0002] Presented herein are methods and compositions for tagmentation of nucleic acids. The transposase compositions and tagmentation methods provided herein have surprisingly improved properties including, for example, generating tagged DNA fragments that are qualitatively and quantitatively representative of the target nucleic acids in the sample from which they are generated.

[0003] Accordingly there is provided a method of claim 1. Discussed herein is a method of sequential tagmentation comprising: (a) providing a first transposome, the first transposome comprising a first transposase enzyme having a first tagmentation profile; (b) combining a target nucleic acid with the first transposase enzyme under conditions suitable for tagmentation, thereby generating a tagmented nucleic acid; (c) combining the tagmented nucleic acid with a second transposome under conditions suitable for tagmentation, the transposome comprising a second transposase enzyme having a tagmentation profile. Suitably, the first tagmentation profile and the second tagmentation profile are different. Suitably, the method comprises a wash step between steps (b) and (c) to substantially separate the tagmented nucleic from reaction buffer used in step (b). In some embodiments, the wash step comprises binding the tagmented nucleic acid to a solid support. In some embodiments, the solid support comprises beads. In some embodiments, the solid support comprises a spin column. In some embodiments, the first transposome and the second transposome have different insertion bias. In some embodiments, step (c) comprises adding the second transposome to a reaction mixture comprising the first transposome.

[0004] Also presented herein is method of tagmentation comprising: (a) providing a first transposome, the first transposome comprising a first transposase enzyme having a first tagmentation profile; (b) providing a second transposome, the second transposome comprising a second transposase enzyme having a second tagmentation profile; (c) combining a target nucleic acid with the first transposome and the second transposome under conditions suitable

for tagmentation, thereby generating a tagmented nucleic acid.

[0005] The details of one or more embodiments are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0006]

Fig. 1 shows a bar graph of the number of unique molecules in EZ-Tn5[™] and EZ-Tn5[™] + Mos1 tagmented DNA libraries prepared using different concentrations of transposomes.

Fig. 2 shows a bar graph of the insert size in the tagmented libraries of Figure 1.

Fig. 3 shows a bar graph of the percent AT dropout and the percent GC dropout in the tagmented libraries of Figure 1.

Fig. 4 shows a plot of the number of unique molecules in tagmented DNA libraries prepared using different tagmentation buffer formulations.

Fig. 5 shows a bar graph of the insert size in the tagmented libraries of Figure 4;

Fig. 6 shows a bar graph of the percent AT dropout and the percent GC dropout in the tagmented libraries of Figure 4.

Fig. 7 shows a bar graph of the total number of reads and diversity in TS-Tn5059 + Mos1 tagmented libraries prepared using different concentrations of transposomes.

Fig. 8 shows a bar graph of insert size in the tagmented libraries of Figure 7.

Fig. 9 shows a bar graph of the percent AT dropout and the percent GC dropout in the tagmented libraries of Figure 7.

Fig. 10 shows a plot of the number of unique molecules in Mos1 + Tn5 sequentially tagmented DNA libraries.

Fig. 11 shows a plot of the insert size in the tagmented libraries of Figure 10;

Fig. 12 shows a plot of the percent AT dropout and the percent GC dropout in the tagmented libraries of Figure 10.

Fig. 13 shows a bar graph of the number of unique molecules in Mos1 + Tn5 tagmented DNA libraries prepared using different concentrations of transposomes; and

Fig. 14 shows a bar graph of the percent AT dropout and the percent GC dropout in the tagmented libraries of Figure 13. Fig. 15 shows HyperMu[™] transposon sequence.

Fig. 16 shows the sequences of HyperMu[™] transposon and various primers used.

Fig. 17 shows the agarose gel electrophoresis analysis of the fragmentation products of bacteriophage genome at varying concentrations of HyperMu[™] transposome.

Fig. 18 shows the agarose gel electrophoresis analysis of the PCR amplified products of tagmented E. Coli chromosome after tagmentation with HyperMu[™] transposome.

Fig. 19 shows the statistics of a sequencing run of E. Coli chromosome using HyperMu[™] tagmentation.

Fig. 20 shows the fragment length distribution after tagmentation of E. Coli chromosome using HyperMu[™].

Fig. 21 shows the uniformity of coverage of Tn5 alone, HyperMu[™] alone, TrueSeq alone, or a combination of HyperMu[™] and Tn5.

Fig. 22 A-D show the sequence bias of TruSeq, HyperMu[™] and Tn5 (Nextera) and compared to a reference tagmentation. The DNA used in reference studies is *E. coli* DNA. % of GC is shown in x-axis and the frequency is shown in y-axis. Fig. 22A is a comparison of the reference with tagmentation results using 3.2ng of HyperMu[™].

Figure 22B is a comparison of the reference with tagmentation results using 1ng of Nextera (Tn5) and 3.2ng of HyperMu[™]. Fig. 22C is a comparison of the reference with TruSeq method. Fig. 22D is a comparison of the reference with Truseq method, tagmentation with Nextera and HyperMu[™].

Fig. 23 shows an exemplary scheme of preparing sequence library by sequential tagmentation using HyperMu[™] and Nextera transposomes.

Fig. 24 shows a plot of fraction of normalized coverage as a function of %GC using Mos-1 tagmentation followed by TsTn5059/Nextera tagmentation. The experiments include two different workflows, one with a clean-up step between two tagmentation steps and the other where the buffer is adjusted by dilution between two tagmentation steps.

Fig. 25 shows a plot of fraction of normalized coverage as a function of %GC using TsTn5059/Nextera tagmentation followed by Mos-1 tagmentation.

Fig. 26 shows a plot of coverage uniformity using various combination of Mos-1 and TsTn5059/Nextera enzymes at various concentrations.

Fig. 27 shows a bar graph of the percent AT dropout and the percent GC dropout in the tagmented libraries using various combinations of TsTn5059/Nextera and Mos-1.

Fig. 28 shows a bar graph showing the diversity in TS-Tn5059/Nextera + Mos1 tagmented

libraries prepared using different concentrations of transposomes.

DETAILED DESCRIPTION

[0007] The transposase compositions and tagmentation methods provided herein have surprisingly improved properties including, for example, generating tagged DNA fragments that are qualitatively and quantitatively representative of the target nucleic acids in the sample from which they are generated.

[0008] Inventors of the present application have surprisingly and unexpectedly found that using two or more transposomes having two or more different tagmentation profiles provides a more uniform tagmentation of a target DNA. The inventors have also found that the use of two or more transposomes is specially advantageous when the tagmentation profiles of the transposases have different insertion biases such as different AT and GC dropout rates.

[0009] In one aspect, the methods disclosed herein include sequential tagmentation comprising: (a) providing a first transposome, the first transposome comprising a first transposon and a first transposase enzyme having a first tagmentation profile; (b) combining a target nucleic acid with the first transposase enzyme under conditions suitable for tagmentation, thereby generating a first tagged nucleic acid; (c) combining the first tagged nucleic acid with a second transposome under conditions suitable for tagmentation, the transposome comprising a second transposon and a second transposase enzyme having a second tagmentation profile, thereby generating a second tagged nucleic acid.

[0010] In some embodiments, the method comprises a wash step between steps (b) and (c) to substantially separate the tagged nucleic from reaction buffer used in step (b). In some embodiments, the wash step comprises binding the tagged nucleic acid to a solid support. In some embodiments, the solid support comprises beads. In some embodiments, the solid support comprises a spin column. In some embodiments, step (c) comprises adding the second transposome to a reaction mixture comprising the first transposome. In some embodiments, one or more first transposases remained bound to the first tagged nucleic acid during the combination of second transposome to the first tagged nucleic acid.

[0011] In one aspect, disclosed herein are methods of preparing a sequencing library. The methods include providing a first transposome, the first transposome comprising a first transposon and a first transposase enzyme having a first tagmentation profile, in which the first transposome is immobilized on a first solid support. A target nucleic acid is combined with the first transposase enzyme under conditions suitable for tagmentation, thereby generating a first tagged nucleic acid. The tagged nucleic acid is combined with a second transposome under conditions suitable for tagmentation, the second transposome comprising a second transposon and a second transposase enzyme having a second tagmentation profile, thereby

generating a second tagmented nucleic acid and creating a sequencing library.

[0012] In one aspect, disclosed herein are methods of preparing a sequencing library. The methods include providing a first transposome, the first transposome comprising a first transposon and a first transposase enzyme having a first tagmentation profile. A target nucleic acid is combined with the first transposase enzyme under conditions suitable for tagmentation, thereby generating a first tagmented nucleic acid. The first tagmented nucleic acid is combined with a second transposome under conditions suitable for tagmentation, the second transposome comprising a second transposon and a second transposase enzyme having a second tagmentation profile, in which the second transposome is immobilized on a second solid support, thereby generating a second tagmented nucleic acid and creating a sequencing library.

[0013] In one aspect, disclosed herein are methods of preparing a sequencing library. The methods include providing a first transposome, the first transposome comprising a first transposon and a first transposase enzyme having a first tagmentation profile. A target nucleic acid is combined with the first transposase enzyme under conditions suitable for tagmentation, thereby generating a first tagmented nucleic acid. The first tagmented nucleic acid is combined with a second transposome under conditions suitable for tagmentation, the transposome comprising a second transposon and a second transposase enzyme having a second tagmentation profile, thereby creating a sequencing library.

[0014] In one aspect, disclosed herein are methods of preparing a sequencing library. The methods include providing a first transposome, the first transposome comprising a first transposon and a first transposase enzyme having a first tagmentation profile. A target nucleic acid is combined with the first transposase enzyme under conditions suitable for tagmentation, thereby generating a first tagmented nucleic acid. The first tagmented nucleic acid is substantially separated from the reaction buffer used for the first tagmentation reaction. The first tagmented nucleic acid is then combined with a second transposome under conditions suitable for tagmentation, the second transposome comprising a second transposons and a second transposase enzyme having a second tagmentation profile, thereby generating a second tagmented nucleic acid. The second tagmented nucleic acid is amplified, thereby generating a sequencing library. In some embodiments, the first set of tagmented nucleic acid is optionally amplified.

[0015] In another aspect, the methods disclosed herein include tagmentation comprising: (a) providing a first transposome, the first transposome comprising a first transposon and a first transposase enzyme having a first tagmentation profile; (b) providing a second transposome, the second transposome comprising a second transposon and a second transposase enzyme having a second tagmentation profile; (c) combining a target nucleic acid with the first transposome and the second transposome under conditions suitable for tagmentation, thereby generating a tagmented nucleic acid. In some embodiments, the first and second transposomes are added simultaneously.

[0016] In some embodiments, the first transposon of the first transposome comprises first adaptor and the second transposon of the second transposome comprises a second adaptor. In some embodiments, the first and the second adaptors are different. In some embodiments, the first and second adaptors comprise a sequence selected from the group consisting of barcodes, primer binding sequences, restriction endonuclease sites, and unique molecular indices.

[0017] In some embodiments, the first, second, or both transposomes are immobilized on a second solid support. Exemplary solid supports include, but are not limited to beads, flow cell surface, spin column, column matrix. In some embodiments, the first surface and the second supports are different. In some embodiments, the first and the second solid supports are beads. In some embodiments, the first transposomes are immobilized on a solid support. In some embodiments, the first transposomes immobilized on a solid support remain bound to the tagmented target nucleic acid and the first tagmented nucleic acids are separated from the solution using the solid support (e.g., streptavidin beads, magnetic beads etc.).

[0018] In some embodiments of the above aspects, the first tagmented nucleic acid is amplified before contacting the second transposome. In some embodiments of the above aspects, the second tagmented nucleic acid is amplified. In some embodiments, two sets of amplification are carried out. In the first set of amplification, the first tagmented nucleic acid is amplified. In the second set of amplification, the second tagmented nucleic acid is further amplified.

[0019] In some embodiments, the first tagmentation profile and the second tagmentation profile are different. In some embodiments, the first transposase and the second transposase have different insertion bias. In some embodiments, the first tagmentation and second profiles have different AT dropout rates. In some embodiments, the first and second tagmentation profiles have different GC dropout rates. In some embodiments, the first tagmentation profile has higher GC dropout rate as compared to the second tagmentation profile. In some embodiments, the first transposase has a greater insertion bias towards AT rich region as compared to the second transposase. In some embodiments, the second tagmentation profile has higher AT dropout rate as compared to the first tagmentation profile. In some embodiments, the second transposase has a greater insertion bias towards GC rich region as compared to the first transposase.

[0020] In some embodiments, the first tagmentation profile has higher AT dropout rate as compared to the second tagmentation profile. In some embodiments, the first transposase has a greater insertion bias towards GC rich region as compared to the second transposase. In some embodiments, the second tagmentation profile has higher GC dropout rate as compared to the first tagmentation profile. In some embodiments, the second transposase has a greater insertion bias towards AT rich region as compared to the second transposase.

[0021] In some embodiments, the reaction buffer used for the first tagmentation reaction is diluted to permit tagmentation reaction with the second transposome. In some embodiments,

the reaction buffer used for the first tagmentation reaction is diluted to at least 1.5-fold, 2-fold, 2.5-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 12.5-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 125-fold, 200-fold, 250-fold, 300-fold or more. In some embodiments, the first tagmented nucleic acid remains immobilized on a solid support during the dilution. In some embodiments, the first tagmented nucleic acid remains bound to one or more first transposases during the dilution. In some embodiments, the first tagmented nucleic acid remains bound to one or more first transposomes and the first transposomes are immobilized on a solid support, thereby immobilizing the first tagmented nucleic acid.

[0022] In some embodiments, the first and second transposomes have different tagmentation profile for a particular genome.

[0023] In some embodiments, the first transposase for the first tagmentation reaction is Mos-1 and the second transposase for the second tagmentation reaction is Tn5 transposase (e.g., EZTn5[™], NexteraV2, or TS-Tn5059).

[0024] In one embodiment, the first transposase for the first tagmentation reaction is Tn5 transposase (e.g., EZTn5[™], NexteraV2, or TS-Tn5059) and a second transposase for the second tagmentation reaction is Mos1 transposase to generate a tagmented DNA library. In one example, the second tagmentation reaction using Mos1 is performed immediately after the first tagmentation reaction using Tn5 (i.e., a clean-up step is not used to remove Tn5 from the DNA before the second tagmentation reaction).

[0025] In another embodiment, the methods of the invention use a first tagmentation reaction using Mos1 transposases followed by a sample clean-up step and a second tagmentation reaction using Tn5 transposases (e.g., EZTn5[™], NexteraV2, or TS-Tn5059) to generate a tagmented DNA library. In one example, the sample clean-up step is a DNA clean-up step performed using the DNA Clean & Concentrator[™] kit (Zymo Research). In this clean-up step, Mos1 is denatured and removed from the DNA. In another example, the sample clean-up step is performed using Agencourt AMPure beads (Beckman Coulter, Inc.). In this example, the clean-up step is a buffer exchange step wherein the Mos1 transposomes remain bound to the DNA.

[0026] In another embodiment, the methods of the invention use a first tagmentation reaction using Mu or HyperMu[™] transposases followed by a sample clean-up step and a second tagmentation reaction using Tn5 transposases (e.g., EZTn5[™], NexteraV2, or TS-Tn5059) to generate a tagmented DNA library. In one example, the sample clean-up step is a DNA clean-up step performed using the DNA Clean & Concentrator[™] kit (Zymo Research). In this clean-up step, Mu or HyperMu[™] is denatured and removed from the DNA. In another example, the sample clean-up step is performed using Agencourt AMPure beads (Beckman Coulter, Inc.). In this example, the clean-up step is a buffer exchange step wherein the Mu or HyperMu[™]

transposases remain bound to the DNA. Figure 23 shows an exemplary scheme of preparing sequence library by sequential tagmentation using HyperMu™ and Nextera transposomes. The input DNA is first subjected to tagmentation using the individually tagged "Mu-Nextera" complex. This library is then amplified via PCR, so that every fragment is represented multiple times in the amplified reaction. The amplified library is taken through a 2nd round of tagmentation with the basic Nextera kit in a concentration regime in which the enzyme is the limiting factor. This guarantees that every single molecule is minimally tagmented with the Nextera complex to preserve maximum continuity information. The generated library is then sequenced. All the Nextera- fragments that have been generated from the same amplicon do share the same barcode (or end-tag), which can be used in the final assembly.

[0027] In some embodiments, the amount of first and the second transposases can be same. In some embodiments, the amount of first and the second transposases can be different.

[0028] In one embodiment, the methods are used for meta-genomics using microbial samples.

Sequential tagmentation to meta-genomics and microbiome

[0029] Sequential tagmentation in all its forms can be applied to microbial samples for meta-genomics applications. In some examples, the performance of a single transposase is highly affected by its bias and the sequence context of the target DNA. If the sample contains multiple species with different DNA sequence compositions, the tagmentation may perform better for some than the other. Genomic DNA for some species may end up with relatively larger or much smaller fragments, which skews their representation on the flowcell. This will cause missing of meta-genomics information. In extreme cases, some species may not have any representation on the flowcell.

[0030] Using sequential tagmentation can help lowering the overall tagmentation bias. In particular, different ratios of the two enzymes can be applied to tweak the library preparation for various genomic compositions. Multiple sequential tagmentations with different enzyme ratios can be applied to the same sample. This helps capturing wider range of species in a microbiome sample. For example, the sample can be split into multiple smaller samples and apply sequential tagmentations with different enzyme ratios on each. Different ratios of enzymes can help better capturing sequencing data of different species in the microbiome sample.

[0031] Furthermore, a quick screen can be established based on fragment size distribution. A microbiome sample (from a certain source, such as gut) can be split into smaller size samples, multiple sequential tagmentations with different enzyme ratios can be applied to each and fragment size distribution for each one can be stored as the baseline. Sample from the same source can be put through the same process and major changes in the fragment size distributions can point towards a major change in the microbiome. This can be used for a quick

test to see whether a microbiome flora from a source is changing.

[0032] As used herein, the term "tagmentation" refers to the modification of DNA by a transposome complex comprising transposase enzyme and transposon end sequence in which the transposon end sequence further comprises adaptor sequence. Tagmentation results in the simultaneous fragmentation of the DNA and ligation of the adaptors to the 5' ends of both strands of duplex fragments.

[0033] Following a purification step to remove the transposase enzyme, additional sequences can be added to the ends of the adapted fragments, for example by PCR, ligation, or any other suitable methodology known to those of skill in the art.

[0034] The method of the invention can use any transposase that can accept a transposase end sequence and fragment a target nucleic acid, attaching a transferred end, but not a non-transferred end. A "transposome" is comprised of at least a transposase enzyme and a transposase recognition site. In some such systems, termed "transposomes", the transposase can form a functional complex with a transposon recognition site that is capable of catalyzing a transposition reaction. The transposase or integrase may bind to the transposase recognition site and insert the transposase recognition site into a target nucleic acid in a process sometimes termed "tagmentation". In some such insertion events, one strand of the transposase recognition site may be transferred into the target nucleic acid.

[0035] In standard sample preparation methods, each template contains an adaptor at either end of the insert and often a number of steps are required to both modify the DNA or RNA and to purify the desired products of the modification reactions. These steps are performed in solution prior to the addition of the adapted fragments to a flowcell where they are coupled to the surface by a primer extension reaction that copies the hybridized fragment onto the end of a primer covalently attached to the surface. These 'seeding' templates then give rise to monoclonal clusters of copied templates through several cycles of amplification.

[0036] The number of steps required to transform DNA into adaptor-modified templates in solution ready for cluster formation and sequencing can be minimized by the use of transposase mediated fragmentation and tagging.

[0037] In some embodiments, transposon based technology can be utilized for fragmenting DNA, for example as exemplified in the workflow for Nextera[™] DNA sample preparation kits (Illumina, Inc.) wherein genomic DNA can be fragmented by an engineered transposome that simultaneously fragments and tags input DNA ("tagmentation") thereby creating a population of fragmented nucleic acid molecules which comprise unique adapter sequences at the ends of the fragments.

[0038] Some embodiments can include the use of a hyperactive Tn5 transposase and a Tn5-type transposase recognition site (Gory shin and Reznikoff, J. Biol. Chem., 273:7367 (1998)), or MuA transposase and a Mu transposase recognition site comprising R1 and R2 end

sequences (Mizuuchi, K., Cell, 35: 785, 1983; Savilahti, H, et al., EMBO J., 14: 4893, 1995). An exemplary transposase recognition site that forms a complex with a hyperactive Tn5 transposase (e.g., EZ-Tn5™ Transposase, Epicentre Biotechnologies, Madison, Wis.).

[0039] More examples of transposition systems that can be used with certain embodiments provided herein include *Staphylococcus aureus* Tn552 (Colegio et al., J. Bacteriol., 183: 2384-8, 2001; Kirby C et al., Mol. Microbiol., 43: 173-86, 2002), Ty1 (Devine & Boeke, Nucleic Acids Res., 22: 3765-72, 1994 and International Publication WO 95/23875), Transposon Tn7 (Craig, N L, Science. 271: 1512, 1996; Craig, N L, Review in: Curr Top Microbiol Immunol., 204:27-48, 1996), Tn/O and IS10 (Kleckner N, et al., Curr Top Microbiol Immunol., 204:49-82, 1996), Mariner transposase (Lampe D J, et al., EMBO J., 15: 5470-9, 1996), Tc1 (Plasterk R H, Curr. Topics Microbiol. Immunol., 204: 125-43, 1996), P Element (Gloor, G B, Methods Mol. Biol., 260: 97-114, 2004), Tn3 (Ichikawa & Ohtsubo, J Biol. Chem. 265:18829-32, 1990), bacterial insertion sequences (Ohtsubo & Sekine, Curr. Top. Microbiol. Immunol. 204: 1-26, 1996), retroviruses (Brown, et al., Proc Natl Acad Sci USA, 86:2525-9, 1989), and retrotransposon of yeast (Boeke & Corces, Annu Rev Microbiol. 43:403-34, 1989). More examples include IS5, Tn10, Tn903, IS911, and engineered versions of transposase family enzymes (Zhang et al., (2009) PLoS Genet. 5:e1000689. Epub 2009 Oct. 16; Wilson C. et al (2007) J. Microbiol. Methods 71:332-5). Additionally, the methods and compositions provided herein are useful with transposase of *Vibrio* species, including *Vibrio harveyi*, as set forth in greater detail in the disclosures of US 2014/0093916 and 2012/0301925. Briefly, a "transposition reaction" is a reaction wherein one or more transposons are inserted into target nucleic acids at random sites or almost random sites. Essential components in a transposition reaction are a transposase and DNA oligonucleotides that exhibit the nucleotide sequences of a transposon, including the transferred transposon sequence and its complement (i.e., the non-transferred transposon end sequence) as well as other components needed to form a functional transposition or transposome complex. The DNA oligonucleotides can further comprise additional sequences (e.g., adaptor or primer sequences) as needed or desired.

[0040] The adapters that are added to the 5' and/or 3' end of a nucleic acid can comprise a universal sequence. A universal sequence is a region of nucleotide sequence that is common to, i.e., shared by, two or more nucleic acid molecules. Optionally, the two or more nucleic acid molecules also have regions of sequence differences. Thus, for example, the 5' adapters can comprise identical or universal nucleic acid sequences and the 3' adapters can comprise identical or universal sequences. A universal sequence that may be present in different members of a plurality of nucleic acid molecules can allow the replication or amplification of multiple different sequences using a single universal primer that is complementary to the universal sequence.

[0041] As used herein the term "at least a portion" and/or grammatical equivalents thereof can refer to any fraction of a whole amount. For example, "at least a portion" can refer to at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9% or 100% of a whole amount.

[0042] As used herein the term "about" means +/- 10%.

Solid Support

[0043] In some embodiments, the solid support or its surface is non-planar, such as the inner or outer surface of a tube or vessel. In some embodiments, the solid support is a surface of a flow cell. In some embodiments, the solid support comprises microspheres or beads. By "microspheres" or "beads" or "particles" or grammatical equivalents herein is meant small discrete particles. Suitable bead compositions include, but are not limited to, plastics, ceramics, glass, polystyrene, methylstyrene, acrylic polymers, paramagnetic materials, thoria sol, carbon graphite, titanium dioxide, latex or cross-linked dextrans such as Sepharose, cellulose, nylon, cross-linked micelles and Teflon, as well as any other materials outlined herein for solid supports may all be used. "Microsphere Detection Guide" from Bangs Laboratories, Fishers Ind. is a helpful guide. In certain embodiments, the microspheres are magnetic microspheres or beads. In some embodiments, the beads can be color coded. For example, MicroPlex® Microspheres from Luminex, Austin, TX may be used.

[0044] The beads need not be spherical; irregular particles may be used. Alternatively or additionally, the beads may be porous. The bead sizes range from nanometers, i.e. 100 nm, to millimeters, i.e. 1 mm, with beads from about 0.2 micron to about 200 microns being preferred, and from about 0.5 to about 5 micron being particularly preferred, although in some embodiments smaller or larger beads may be used. In some embodiments, beads can be about 1, 1.5, 2, 2.5, 2.8, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 15, or 20 µm in diameter.

Barcodes

[0045] Generally, a barcode can include one or more nucleotide sequences that can be used to identify one or more particular nucleic acids. The barcode can be an artificial sequence, or can be a naturally occurring sequence generated during transposition, such as identical flanking genomic DNA sequences (g-codes) at the end of formerly juxtaposed DNA fragments. In some embodiments, a barcode is an artificial sequence that is non-natural to the target nucleic acid and is used to identify the target nucleic acid or determine the contiguity information of the target nucleic acid.

[0046] A barcode can comprise at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more consecutive nucleotides. In some embodiments, a barcode comprises at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more consecutive nucleotides. In some embodiments, at least a portion of the barcodes in a population of nucleic acids comprising barcodes is different. In some embodiments, at least about 10%, 20%, 30%, 40%, 50%, 60%,

70%, 80%, 90%, 95%, 99% of the barcodes are different. In more such embodiments, all of the barcodes are different. The diversity of different barcodes in a population of nucleic acids comprising barcodes can be randomly generated or non-randomly generated.

[0047] In some embodiments, a transposon sequence comprises at least one barcode. In some embodiments, such as transposomes comprising two non-contiguous transposon sequences, the first transposon sequence comprises a first barcode, and the second transposon sequence comprises a second barcode. In some embodiments, a transposon sequence comprises a barcode comprising a first barcode sequence and a second barcode sequence. In some of the foregoing embodiments, the first barcode sequence can be identified or designated to be paired with the second barcode sequence. For example, a known first barcode sequence can be known to be paired with a known second barcode sequence using a reference table comprising a plurality of first and second bar code sequences known to be paired to one another.

[0048] In another example, the first barcode sequence can comprise the same sequence as the second barcode sequence. In another example, the first barcode sequence can comprise the reverse complement of the second barcode sequence. In some embodiments, the first barcode sequence and the second barcode sequence are different. The first and second barcode sequences may comprise a bi-code.

[0049] In some embodiments of compositions and methods described herein, barcodes are used in the preparation of template nucleic acids. As will be understood, the vast number of available barcodes permits each template nucleic acid molecule to comprise a unique identification. Unique identification of each molecule in a mixture of template nucleic acids can be used in several applications. For example, uniquely identified molecules can be applied to identify individual nucleic acid molecules, in samples having multiple chromosomes, in genomes, in cells, in cell types, in cell disease states, and in species, for example, in haplotype sequencing, in parental allele discrimination, in metagenomics sequencing, and in sample sequencing of a genome.

[0050] Exemplary barcode sequences include, but are not limited to TATAGCCT, ATAGAGGC, CCTATCCT, GGCTCTGA, AGGCGAAG, TAATCTTA, CAGGACGT, and GTACTGAC.

Target nucleic acids

[0051] A target nucleic acid can include any nucleic acid of interest. Target nucleic acids can include DNA, RNA, peptide nucleic acid, morpholino nucleic acid, locked nucleic acid, glycol nucleic acid, threose nucleic acid, mixed samples of nucleic acids, polyploidy DNA (i.e., plant DNA), mixtures thereof, and hybrids thereof. In a preferred embodiment, genomic DNA or amplified copies thereof are used as the target nucleic acid. In another preferred embodiment, cDNA, mitochondrial DNA or chloroplast DNA is used.

[0052] A target nucleic acid can comprise any nucleotide sequence. In some embodiments, the target nucleic acid comprises homopolymer sequences. A target nucleic acid can also include repeat sequences. Repeat sequences can be any of a variety of lengths including, for example, 2, 5, 10, 20, 30, 40, 50, 100, 250, 500 or 1000 nucleotides or more. Repeat sequences can be repeated, either contiguously or non-contiguously, any of a variety of times including, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 times or more.

[0053] Some embodiments described herein can utilize a single target nucleic acid. Other embodiments can utilize a plurality of target nucleic acids. In such embodiments, a plurality of target nucleic acids can include a plurality of the same target nucleic acids, a plurality of different target nucleic acids where some target nucleic acids are the same, or a plurality of target nucleic acids where all target nucleic acids are different. Embodiments that utilize a plurality of target nucleic acids can be carried out in multiplex formats so that reagents are delivered simultaneously to the target nucleic acids, for example, in one or more chambers or on an array surface. In some embodiments, the plurality of target nucleic acids can include substantially all of a particular organism's genome. The plurality of target nucleic acids can include at least a portion of a particular organism's genome including, for example, at least about 1%, 5%, 10%, 25%, 50%, 75%, 80%, 85%, 90%, 95%, or 99% of the genome. In particular embodiments the portion can have an upper limit that is at most about 1%, 5%, 10%, 25%, 50%, 75%, 80%, 85%, 90%, 95%, or 99% of the genome

[0054] Target nucleic acids can be obtained from any source. For example, target nucleic acids may be prepared from nucleic acid molecules obtained from a single organism or from populations of nucleic acid molecules obtained from natural sources that include one or more organisms. Sources of nucleic acid molecules include, but are not limited to, organelles, cells, tissues, organs, organisms, single cell, or a single organelle. Cells that may be used as sources of target nucleic acid molecules may be prokaryotic (bacterial cells, for example, *Escherichia*, *Bacillus*, *Serratia*, *Salmonella*, *Staphylococcus*, *Streptococcus*, *Clostridium*, *Chlamydia*, *Neisseria*, *Treponema*, *Mycoplasma*, *Borrelia*, *Legionella*, *Pseudomonas*, *Mycobacterium*, *Helicobacter*, *Erwinia*, *Agrobacterium*, *Rhizobium*, and *Streptomyces* genera); archaeon, such as crenarchaeota, nanoarchaeota or euryarchaeotia; or eukaryotic such as fungi, (for example, yeasts), plants, protozoans and other parasites, and animals (including insects (for example, *Drosophila* spp.), nematodes (e.g., *Caenorhabditis elegans*), and mammals (for example, rat, mouse, monkey, non-human primate and human). Target nucleic acids and template nucleic acids can be enriched for certain sequences of interest using various methods well known in the art. Examples of such methods are provided in Int. Pub. No. WO/2012/108864. In some embodiments, nucleic acids may be further enriched during methods of preparing template libraries. For example, nucleic acids may be enriched for certain sequences, before insertion of transposomes after insertion of transposomes and/or after amplification of nucleic acids.

[0055] In addition, in some embodiments, target nucleic acids and/or template nucleic acids can be highly purified, for example, nucleic acids can be at least about 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% free from contaminants before use with the methods provided

herein. In some embodiments, it is beneficial to use methods known in the art that maintain the quality and size of the target nucleic acid, for example isolation and/or direct transposition of target DNA may be performed using agarose plugs. Transposition can also be performed directly in cells, with population of cells, lysates, and non-purified DNA.

[0056] In some embodiments, target nucleic acid can be from a single cell. In some embodiments, target nucleic acid can be from formalin fixed paraffin embedded (FFPE) tissue sample. In some embodiments, target nucleic acid can be cross-linked nucleic acid. In some embodiments, the target nucleic acid can be cross-linked to nucleic acid. In some embodiments, the target nucleic acid can be cross-linked to proteins. In some embodiments, the target nucleic acid can be cell-free nucleic acid. Exemplary cell-free nucleic acid include but are not limited to cell-free DNA, cell-free tumor DNA, cell-free RNA, and cell-free tumor RNA.

[0057] In some embodiments, target nucleic acid may be obtained from a biological sample or a patient sample. The term "biological sample" or "patient sample" as used herein includes samples such as tissues and bodily fluids. "Bodily fluids" may include, but are not limited to, blood, serum, plasma, saliva, cerebral spinal fluid, pleural fluid, tears, lactal duct fluid, lymph, sputum, urine, amniotic fluid, and semen. A sample may include a bodily fluid that is "acellular." An "acellular bodily fluid" includes less than about 1% (w/w) whole cellular material. Plasma and serum are examples of acellular bodily fluids. A sample may include a specimen of natural or synthetic origin (i.e., a cellular sample made to be acellular).

[0058] The term "Plasma" as used herein refers to acellular fluid found in blood. "Plasma" may be obtained from blood by removing whole cellular material from blood by methods known in the art (e.g., centrifugation, filtration, and the like).

Methods of use

[0059] The transposases presented herein can be used in a sequencing procedure, such as an *in vitro* transposition technique. Briefly, *in vitro* transposition can be initiated by contacting a transposome complex and a target DNA. Exemplary transposition procedures and systems that can be readily adapted for use with the transposases of the present disclosure are described, for example, in WO 10/048605; US 2012/0301925; US 2013/0143774. For example, in some embodiments, the transposase enzymes presented herein can be used in a method for generating a library of tagged DNA fragments from target DNA comprising any dsDNA of interest (e.g., for use as next-generation sequencing or amplification templates), the method comprising: incubating the target DNA in an *in vitro* transposition reaction with at least one transposase and a transposon end composition with which the transposase forms a transposition complex, the transposon end composition comprising (i) a transferred strand that exhibits a transferred transposon end sequence and, optionally, an additional sequence 5'-of the transferred transposon end sequence, and (ii) a non-transferred strand that exhibits a sequence that is complementary to the transferred transposon end sequence, under conditions and for sufficient time wherein multiple insertions into the target DNA occur, each of

which results in joining of a first tag comprising or consisting of the transferred strand to the 5' end of a nucleotide in the target DNA, thereby fragmenting the target DNA and generating a population of annealed 5'-tagged DNA fragments, each of which has the first tag on the 5'-end; and then joining the 3'-ends of the 5'-tagged DNA fragments to the first tag or to a second tag, thereby generating a library of tagged DNA fragments (e.g., comprising either tagged circular ssDNA fragments or 5'- and 3'-tagged DNA fragments (or "di-tagged DNA fragments")).

[0060] As used herein the term "diversity" refers to the number of unique molecules in a library. In some embodiments, diversity is an indication of the diversity (complexity) of the library.

[0061] As used herein "insert size" means average fragment size for the library. The mode and mean insert sizes were determined based on sequencing data, after determining the length of the sequenced insert. In some embodiments, fragment size is determined using a BioAnalyzer.

[0062] As used herein "GC dropout" means the percentage of GC rich regions in the genome that are dropped (absent) from the tagged library.

[0063] As used herein "AT dropout" means the percentage of AT rich regions in the genome that are dropped (absent) from the tagged library.

[0064] As used herein, the term "insertion bias" refers to the sequence preference of a transposase for insertion sites. For example, if the background frequency of A/T/C/G in a polynucleotide sample is equally distributed (25% A, 25% T, 25% C, 25% G), then any over-representation of one nucleotide over the other three at a transposase binding site or cleavage site reflects an insertion bias at that site. Insertion bias can be measured using any one of a number of methods known in the art. For example, the insertion sites can be sequenced and the relative abundance of any particular nucleotide at each position in an insertion site can be compared.

[0065] Unless otherwise specified, the terms "a" or "an" mean "one or more" throughout this application.

EXAMPLES

Example 1

Tn5 and Mos1 Sequential Tagmentation

Tn5 tagmentation followed by Mos1 tagmentation

[0066] In some experiments, first tagmentation reaction using Tn5 transposomes (e.g., EZTn5[™], NexteraV2, or TS-Tn5059) and a second tagmentation reaction using Mos1 transposomes to generate a tagmented DNA library. In one example, the second tagmentation reaction using Mos1 is performed immediately after the first tagmentation reaction using Tn5 (i.e., a clean-up step is not used to remove Tn5 from the DNA before the second tagmentation reaction). The Tn5 enzyme used was either EZTn5, Tn5 from Nextera V2 kit, or mutant TS-Tn5059.

[0067] To evaluate the effect of sequential tagmentation using Tn5 and Mos1 transposomes on library output and sequencing metrics, tagmented DNA libraries were constructed using *Bacillus cereus* genomic DNA. For each sequentially tagmented library, a first tagmentation reaction was performed by mixing 20 µL *B. cereus* genomic DNA (50 ng), 25 µL 2x standard tagmentation buffer (2x TD; 20 mM Tris Acetate, pH 7.6, 10 mM MgCl₂, and 20% dimethylformamide (DMF)), and various concentrations of EZ-Tn5[™] transposomes (Epicentre) in a total reaction volume of 50 µL. EZ-Tn5[™] transposome was used at final concentrations of 3, 6, 12, 25, 50, and 100 nM. Reactions were incubated at 55 °C for 5 minutes. After completion of the first tagmentation reaction, a second tagmentation reaction using Mos1 transposomes was performed. Mos1 transposome was used at final concentrations of 20 and 100 nM. Reactions using Mos1 also included the addition of NaCl at a final concentration of 200 mM. Reactions were incubated at 30 °C for 60 minutes.

[0068] For each Tn5 control library, a tagmentation reaction was performed by mixing 20 µL *B. cereus* genomic DNA, 25 µL 2x standard tagmentation buffer, and 5 µL of EZ-Tn5[™] (25 nM) or NexteraV2 (25 nM) transposomes in a total reaction volume of 50 µL. Reactions were incubated at 55 °C for 5 minutes.

[0069] Following the tagmentation reaction, the samples were processed according to the rest of the standard Nextera[™] sample preparation protocol (after tagmentation reaction) Libraries were sequenced by sequencing-by-synthesis (SBS) and evaluated by standard next generation sequencing analysis tools. Fragment size distribution in each library was also evaluated on a Bioanalyzer.

[0070] Figure 1 shows a bar graph 100 of the number of unique molecules in EZ-Tn5[™] and EZ-Tn5[™] + Mos1 tagmented DNA libraries prepared using different concentrations of transposomes. The number of unique molecules in a library is an indication of the diversity (complexity) of the library. Each bar on the graph represents a tagmented library. Control libraries (i.e., libraries that were prepared using standard reaction conditions of 25 nM EZ-Tn5[™] or NexteraV2 transposomes) are designated by "std". Libraries that were prepared using different concentrations of EZ-Tn5[™] are designated by "EZTn5 - enzyme concentration". For example, the third bar in bar graph 100 is labeled "EZTn5 - 100nM" and designates a library

that was prepared using EZ-Tn5™ at a final concentration of 100 nM. Libraries that were prepared using sequential tagmentation with EZ-Tn5™ followed by Mos1 are designated by "EZTn5 - enzyme concentration - Mos1 - enzyme concentration". For example, the ninth bar in bar graph 100 is labeled "EZTN5 - 100nM - Mos1 - 20nM" and designates a library that was prepared using EZ-Tn5™ at a final concentration of 100 nM followed by tagmentation using Mos1 at a final concentration of 20 nM. All libraries were prepared using the standard buffer formulation. A line 110 indicates a standard level of diversity obtained in a Tn5 tagged DNA library.

[0071] The data show that tagmented libraries prepared using EZ-Tn5™ at 12nM-50nM and Mos1 sequential tagmentation at 20nM have a higher average diversity compared to control libraries and libraries prepared using EZ-Tn5™ alone. For example, the "EZTn5 - 25nM - Mos1- 20nM" library has about a two-fold increase in diversity compared to control libraries or libraries prepared using EZ-Tn5™ alone.

[0072] Figure 2 shows a bar graph 200 of the insert size in the tagmented libraries of Figure 1. The median value and mode value for each tagmented library were generated from the SBS data. Because the median and mode values were generated from the SBS data, only those inserts that were amplified in the cluster amplification process and sequenced are represented. The "BA" value was generated from a Bioanalyzer trace of the fragment size distribution in each tagmented sample. Because the "BA" value was generated from the Bioanalyzer trace, all fragments generated in the tagmentation reaction are represented (i.e., larger fragments that may not be represented in the SBS data). The data show that there is variability in the insert size in libraries prepared using different concentrations of transposomes. The data also shows that in the "EZTn5 - 25nM - Mos1- 20nM", which is the library with the highest level of diversity (Figure 1), the insert size is about the same as the insert size in the "EZTn5-25nM" library.

[0073] Figure 3 shows a bar graph 300 of the percent AT dropout and the percent GC dropout in the tagmented libraries of Figure 1. AT dropout may be defined as the percentage of AT rich regions in the genome that are not present in the tagmented library. GC dropout may be defined as the percentage of GC rich regions in the genome that are not present in the tagmented library. A line 310 indicates a standard threshold of AT dropout obtained in a standard Tn5 tagmentation reaction. In a standard Tn5 tagmentation reaction, GC dropout is not typically observed. The data show that there is variability in the percent AT and GC dropout prepared using different transposome concentrations. The data also shows that in the "EZTn5 - 25nM - Mos1- 20nM", which is the library with the highest level of diversity (Figure 1), the percent AT and GC dropout is substantially lower than the percent dropout in the control libraries, e.g., "EZTn5-std-bcereus", "NexteraV2-std-bcereus", and "EZTn5-25nM".

[0074] To evaluate the effect of tagmentation buffer composition on library output and sequencing metrics, *B. cereus* tagmented libraries were prepared using modified formulations of the standard tagmentation buffer. The buffer formulations were as follows standard buffer (TD) (10 mM Tris Acetate, pH 7.6, 5 mM MgCl₂, and 10% DMF); manganese buffer (Mn; 10

mM Tris Acetate, pH 7.6, 5 mM MnCl₂, and 10% DMF); cobalt buffer (Co; 10 mM Tris Acetate, pH 7.6, 5 mM CoCl₂, and 10% DMF); and nickel buffer (Ni; 10 mM Tris Acetate, pH 7.6, 5 mM NiCl₂, and 10% DMF).

[0075] Figure 4 shows a plot 400 of the number of unique molecules in tagged DNA libraries prepared using different tagmentation buffer formulations. Control libraries that were prepared using the standard tagmentation buffer and volume of transposomes (5 μ L = 25 nM transposome) are designated "EZTn5 - std - bcereus" and "NexteraV2 - std - bcereus". Libraries that were prepared using different volumes (i.e., 10 μ L or 15 μ L; or 50 nM and 75 nM, respectively) of NexteraV2 transposome and the standard tagmentation buffer formulation are designated by "NexteraV2 - 10 μ L" and "NexteraV2 - 15 μ L". NexteraV2 libraries that were prepared using a modified (e.g., Mn, Co, or Ni) tagmentation buffer formulation are designated by "NexteraV2 - modification" or a "NexteraV2 - modification - μ L", where " μ L" designates the volume of transposome used in the reaction. Libraries that were prepared using sequential tagmentation with NexteraV2 (25 nM) and Mos1 are designated by "NexteraV2 - MBPMos 1 - 20 nM - Mn", where 20 nM is the concentration of Mos1 transposome and "Mn" is the manganese buffer formulation. The sequential tagmentation library reaction was repeated three times (n = 3) and the individual libraries are designated as a, b or c.

[0076] The data show that NexteraV2-tagmented libraries prepared using a tagmentation buffer that includes CoCl₂ have a higher diversity compared to libraries prepared in buffers without the addition of CoCl₂ (i.e., the standard tagmentation buffer and buffers that include MnCl₂ or NiCl₂). The data also shows that libraries prepared using sequential tagmentation with NexteraV2 and Mos1 in Mn buffer have a higher diversity compared to tagged libraries prepared with NexteraV2 alone in Mn buffer.

[0077] Figure 5 shows a bar graph 500 of the insert size in the tagged libraries of Figure 4. The data show that insert size in NexteraV2-tagmented libraries prepared using tagmentation buffers that include either CoCl₂ or NiCl₂ are relatively larger compared to tagged libraries prepared using the standard or Mn buffer formulations. The data also show that in the "NexteraV2 - MBPMos 1 - 20 nM - Mn" sequentially tagged libraries the insert size is about the same as the NexteraV2 control library ("NexteraV2 - std - bcereus") and NexteraV2 library prepared in Mn buffer ("NexteraV2 - Mn").

[0078] Referring now to Figure 4 and Figure 5, the data also shows that in sequentially-tagmented libraries prepared using the Mn buffer formulation (NexteraV2 - MBPMos1 - 20 nM - Mn), library diversity is increased (relative to control levels) while the insert size in the library remains about the same (relative to control levels).

[0079] Figure 6 shows a bar graph 600 of the percent AT dropout and the percent GC dropout in the tagged libraries of Figure 4. The data show that in the libraries prepared using Mn buffer and sequential tagmentation with NexteraV2 and Mos1 (i.e., "EZTn5 - 25nM - Mos1-20nM") there is a substantial decrease in the percent AT dropout and a slight increase in the percent GC dropout compared to libraries prepared using NexteraV2 alone and either the

standard tagmentation buffer (i.e., "NexteraV2 - std - bcereus") or Mn buffer ("NexteraV2 - Mn).

[0080] Referring now to Figures 4 through 6, the data shows that in the sequentially-tagmented libraries prepared using the Mn buffer formulation (NexteraV2 - MBPMos1 - 20 nM - Mn), library diversity (Figure 4) is increased while the insert size (Figure 5) in the library remains about the same, and the percent AT dropout (Figure 6) is substantially reduced.

[0081] In another example, the Tn5 transposome TS-Tn5059 and Mos1 were used to generate sequentially-tagmented *B. cereus* libraries. In this example, a first tagmentation reaction was performed using TS-TN5059 at final concentrations of 40 nM, 80 nM, and 240 nM. A second tagmentation reaction was performed using Mos1 at final concentrations of 10 and 20 nM. All libraries were prepared using the standard buffer formulation. Reactions using Mos1 also included the addition of NaCl at a final concentration of 200 mM. Following the tagmentation reaction, the samples were processed according to the standard Nextera™ sample preparation protocol. Libraries were evaluated by SBS on a MiSeq instrument (Illumina, Inc.). Fragment size distribution in each library was also evaluated on a Bioanalyzer.

[0082] Figure 7 shows a bar graph 700 of the total number of reads and diversity in TS-Tn5059 + Mos1 tagmented libraries prepared using different concentrations of transposomes. The total number of reads is the total number of reads from the flow cell. The diversity is the number of unique molecules in the library and is used as an indication of library complexity. Each pair of bars on the graph represents a tagmented library. Libraries that were prepared using sequential tagmentation with TS-Tn5059 and Mos1 are designated by "TS-Tn5059 - enzyme concentration - Mos1 - enzyme concentration". EZTn5™ and NexteraV2 were used to prepare comparative control libraries (e.g., "EZTn5 - std - bcereus" and "NexteraV2 - std - bcereus"). "NexteraV2 - SSB - bcereus" designates a library that was prepared using the standard volume (5 µL) of transposome, but included an additional 10 µl of SSB diluent. "NexteraV2 - 15µL - bcereus" designates a library that was prepared using 15 µL (75 nM) of NexteraV2 transposome. All libraries were prepared using the standard buffer formulation.

[0083] The data shows that the diversity in the TS-Tn5059 - 240nM - Mos1 - 20nM library is higher compared to the diversity in the EZTn5™ and NexteraV2 control libraries.

[0084] Figure 8 shows a bar graph 800 of insert size in the tagmented libraries of Figure 7. This graph shows the effect of Mos1 concentration to the final insert sizes. A Mos1 concentration of the range 10 - 20nM does not have a major impact on the insert sizes. Figure 9 shows a bar graph 900 of the percent AT dropout and the percent GC dropout in the tagmented libraries of Figure 7. The data show that in general the libraries prepared using sequential tagmentation there is a substantial decrease in the percent AT dropout and a slight increase in the percent GC dropout compared to the NexteraV2 control libraries. For example, the percent AT dropout in the TS-Tn5059 - 40nM - Mos1 - 20nM is substantially decreased and the percent GC dropout slightly increased compared to the NexteraV2 -std -bcereus

library.

Example 2

Generating Sequencing Library with Mu Transposome Complex

[0085] HyperMu[™] (Epicentre, Madison, WI), a mutant Mu transposase is used to generate sequencing library. HyperMu[™] Transposase, a hyperactive enzyme that retains the highly random insertion characteristics of MuA transposase but is at least 50-times more active in vitro than the enzyme available from other suppliers. Upon Mu transposition, the transposon arms (i.e. RI and RII) together with any attached sequence would be transferred to the template DNA, at the same time fragmenting the template. HyperMu[™] transposon sequence and the primer sequences are shown in Fig. 15-16. The Tn5 enzyme used was EZTn5, Tn5 from Nextera V2 kit.

Assessing Activity of Mu Transposome

[0086] The tagmentation capacity of HyperMu[™] transposome is assessed on a ~50 kb bacteriophage genome. The tagmentation reaction was carried out in TA buffer for one hour at 37°C at increasing concentration of HyperMu[™] transposome. The fragmentation products were analyzed by agarose gel electrophoresis and the results are shown in Fig. 17.

[0087] The HyperMu[™] complexes were used to tagment E. coli chromosome and the tagged fragments were amplified to introduce sequencing adapters. 25 cycles of PCR were carried out using P5-MUTS and P7-MLJTS primers. The PCR products are analyzed by agarose gel electrophoresis and shown in Fig. 18. PCR products were observed with different amounts of input DNA.

Analysis of PCR amplified tagmented DNA

[0088] A 3.2 ng DNA was used for paired end sequencing on GAIIIX (2X35 bp). The sample was sequenced on a single lane on GA. The total number of reads was 30,071,951 and number of unique reads <2000 bp was 4,599,874. The statistics of the sequencing run is shown in Fig. 19. The average size of the fragments sequenced was much longer than Nextera, and was close to 800bp as shown in Fig. 20.

[0089] The uniformity of the sequencing run was better for HyperMu[™] compared to Tn5. The

uniformity of the sequencing run was better for HyperMu™ with Tn5 as compared to HyperMu™ or Tn5 alone. The uniformity of the sequencing run was comparable to TruSeq. The results are shown in Fig. 21. The observed GC bias for HyperMu™ is similar to Tn5 and shown in Fig. 22.

[0090] The experiments set forth in Figures 1-5 were performed to characterize the effect of Tn5 tagmentation buffer composition and reaction conditions on library output and sequencing metrics. In particular, in experiments set forth in Figs. 1-3, Mos-1 was added to Tn5 tagmentation reactions. The Tn5 enzyme used was EZTn5, Tn5 from Nextera V2 kit, or mutant TS-Tn5059.

[0091] In experiments set forth in Figs. 4 and 5, Mos-1 tagmentation reaction was performed first, and the tagmented DNA was washed to remove tagmentation buffer from the first reaction. Subsequently, the tagmented DNA was further tagmented using a Tn5 enzyme (EZTn5, Tn5 from Nextera V2 kit, or mutant TS-Tn5059). Various wash methods tested included Ampure beads and Zymo Clean and Concentrator kit (Zymo).

[0092] To evaluate the effect of tagmentation buffer composition and reaction conditions on library output and sequencing metrics, Tn5 tagmented DNA libraries were constructed using *Bacillus cereus* genomic DNA. Each tagmented library was prepared using 25 ng input of *B. cereus* genomic DNA. The genomic content of *B. cereus* is about 40% GC and about 60% AT.

[0093] Tagmentation buffers were prepared as 2x formulations. For each library, a tagmentation reaction was performed by mixing 20 µL *B. cereus* genomic DNA (25 ng), 25 µL 2x tagmentation buffer, and 5 µL enzyme (10x Ts-Tn5059 or 10x Ts-Tn5) in a total reaction volume of 50 µL. Reactions were incubated at 55 °C for 5 minutes. Following the tagmentation reaction, the samples were processed according to the standard Nextera™ sample preparation protocol. Libraries were sequenced using Illumina's SBS (sequencing-by-synthesis) chemistry on a MiSeq device. Sequencing runs were 2x71 cycles using a V2 MiSeq kit. Fragment size distribution in each library was evaluated on a Bioanalyzer.

Example 3

Tn5 and Mos1 Sequential Tagmentation in Solution

[0094] Tn5 transposases have decreased activity in buffers that contain >50mM NaCl and Mos1 transposases have decreased activity in buffers that contain <150mM NaCl. A sequential tagmentation to optimize the activity of both enzyme can be carried out.

Tn5 tagmentation followed by Mos1 tagmentation

[0095] Standard Nextera™ (Epicentre, Madison, WI) tagmentation using conditions and buffers specified in the Nextera library prep protocols are used. After the initial Tn5 tagmentation, the reaction temperature is reduced to <30°C. Concentrated NaCl is then added to the reaction to a final concentration of 150-300mM. Mos1 transposome is then added to the tagmentation reaction and the reaction is incubated at 30°C. Once tagmentation is complete, the reaction is cleaned-up either using Ampure™ beads (Beckman Coulter, CA, USA) or Zymo Clean & Concentrator™ cartridges (Zymo Research, Irvine, CA). The remaining protocol for adaptor addition through PCR and final clean-up and size selection is specified in the Nextera™ library prep protocol.

Mos1 tagmentation followed by clean-up to remove the high salt buffer, followed by Tn5 tagmentation

[0096] Standard Nextera™ (Epicentre, Madison, WI) buffers are used with the inclusion of 150-300mM NaCl for Mos1 optimal activity. Mos1 is then added to the reaction and incubated at 30°C. Post tagmentation, the reaction is cleaned-up using Ampure™ beads (Beckman Coulter, CA, USA) or Zymo Clean & Concentrator™ cartridges (Zymo Research, Irvine, CA), or similar methods for DNA purification. The cleaned-up fragmented DNA material is then used as the DNA input for the secondary tagmentation using Tn5 or Tn5 mutant transposomes. After the second tagmentation, the reaction is cleaned-up either using Ampure™ beads (Beckman Coulter, CA, USA) or Zymo Clean & Concentrator™ cartridges (Zymo Research, Irvine, CA), or similar methods. The remaining protocol for adaptor addition through PCR and final clean-up and size selection is specified in the Nextera™ library prep protocol (Epicentre, Madison, WI).

Mos1 tagmentation followed by a dilution to reduce the high salt buffer, followed by Tn5 tagmentation

[0097] Standard Nextera™ buffers (Epicentre, Madison, WI) are used with the inclusion of 150-300 mM NaCl for Mos1 optimal activity. Mos1 is then added to the reaction and incubated at 30°C. Post tagmentation, the reaction is diluted with reaction buffer to reduce the NaCl concentration to ≤50mM. Tn5 is then added to the tagmentation reaction and incubated at ≤55°C. After the second tagmentation, the reaction is clean-up either using Ampure™ beads (Beckman Coulter, CA, USA) or Zymo Clean & Concentrator™ cartridges (Zymo Research, Irvine, CA), or similar DNA purification methods. The remaining protocol for adaptor addition through PCR and final clean-up and size selection is specified in the Nextera library prep protocol™ (Epicentre, Madison, WI).

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO9523875A](#) [0039]
- [US20140093916A](#) [0039]
- [US20120301925A](#) [0039] [0059]
- [WO2012108864A](#) [0054]
- [WO10048605A](#) [0059]
- [US20130143774A](#) [0059]

Non-patent literature cited in the description

- COLEGIO et al. J. Bacteriol., 2001, vol. 183, 2384-8 [0039]
- KIRBY C et al. Mol. Microbiol., 2002, vol. 43, 173-86 [0039]
- DEVINEBOEKENucleic Acids Res., 1994, vol. 22, 3765-72 [0039]
- CRAIG, N L Science, 1996, vol. 271, 1512- [0039]
- CRAIG, N L Review in: Curr Top Microbiol Immunol., 1996, vol. 204, 27-48 [0039]
- KLECKNER N et al. Curr Top Microbiol Immunol., 1996, vol. 204, 49-82 [0039]
- LAMPE D J et al. EMBO J., 1996, vol. 15, 5470-9 [0039]
- PLASTERK R H Curr. Topics Microbiol. Immunol., 1996, vol. 204, 125-43 [0039]
- GLOOR, G B Methods Mol. Biol., 2004, vol. 260, 97-114 [0039]
- ICHIKAWA O HTS SUBO J Biol. Chem., 1990, vol. 265, 18829-32 [0039]
- OHTSUBO SEKINE Curr. Top. Microbiol. Immunol., 1996, vol. 204, 1-26 [0039]
- BROWN et al. Proc Natl Acad Sci USA, 1989, vol. 86, 2525-9 [0039]
- BOEKE CORCES Annu Rev Microbiol., 1989, vol. 43, 403-34 [0039]
- ZHANG et al. PLoS Genet., 2009, vol. 5, e1000689- [0039]

- WILSON C. et al. J. Microbiol. Methods, 2007, vol. 71, 332-5 [\[0039\]](#)

PATENTKRAV

1. Fremgangsmåde til fremstilling af et sekventeringsbibliotek, hvilken fremgangsmåde omfatter:

- (a) tilvejebringelse af et første transposom, idet det første transposom omfatter
5 et første transposon og et første transposaseenzym med en første tagmenteringsprofil;
 - (b) kombination af en målnukleinsyre med det første transposaseenzym under betingelser, der er egnet til tagmentering, hvorved der genereres en første tagmenteret nukleinsyre;
 - 10 (c) separering, i det væsentlige, af den første tagmenterede nukleinsyre fra reaktionsbuffer, der anvendes i trin (b);
 - (d) kombination af den første tagmenterede nukleinsyre med et andet transposom under betingelser, der er egnet til tagmentering, idet det andet transposom omfatter et andet transposon og et andet transposaseenzym med en
15 anden tagmenteringsprofil, hvorved der genereres en anden tagmenteret nukleinsyre;
 - (e) amplificering af den anden tagmenterede nukleinsyre, hvorved der genereres et sekventeringsbibliotek.
2. Fremgangsmåde ifølge krav 1, der endvidere eventuelt omfatter amplificering af den første tagmenterede nukleinsyre.
- 20 3. Fremgangsmåde ifølge et hvilket som helst af kravene 1-2, hvor det første, det andet eller begge transposomer er immobiliseret på faste bærere, eventuelt hvor de faste bærere er perler.
4. Fremgangsmåde ifølge et hvilket som helst af kravene 1-3, hvor det første transposon omfatter en første adaptor, eller det andet transposon omfatter
25 en anden adaptor.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1-3, hvor det første transposon omfatter en første adaptor, og det andet transposon omfatter en anden adaptor, hvor den første og den anden adaptor er forskellige.

6. Fremgangsmåde ifølge et hvilket som helst af kravene 1-5, hvor den første og den anden adaptor omfatter en sekvens, der er valgt fra gruppen bestående af barcodes, primerbindingssekvenser, restriktionsendonukleasesteder og unikke molekylære indeks.
- 5 7. Fremgangsmåde ifølge et hvilket som helst af kravene 1-6, hvor det første eller det andet transposaseenzym er valgt fra gruppen bestående af Mos-1, HyperMu™, Tn5, Ts-Tn5, Ts-Tn5059, Hermes, Tn7.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1-7, hvor reaktionsbuffer, der anvendes i trin (b), fortyndes for at tillade
- 10 tagmenteringsreaktion med det andet transposom.
9. Fremgangsmåde ifølge et hvilket som helst af kravene 1-7, hvor det andet transposom kombineres til en reaktionsblanding, der omfatter det første transposom og den første tagmenterede nukleinsyre.
10. Fremgangsmåde ifølge krav 9, hvor én eller flere første transposase
- 15 forbliver bundet til den første tagmenterede nukleinsyre under kombination af den første tagmenterede nukleinsyre med et andet transposom.
11. Tagmenteringsfremgangsmåde, der omfatter:
- (a) tilvejebringelse af et første transposom, idet det første transposom omfatter et første transposon og et første transposaseenzym med en første
- 20 tagmenteringsprofil;
- (b) tilvejebringelse af et andet transposom, idet det andet transposom omfatter et andet transposon og et andet transposaseenzym med en anden tagmenteringsprofil;
- (c) kombination af en målnukleinsyre med det første transposom og det andet transposom under betingelser, der er egnet til tagmentering, hvorved der
- 25 genereres en tagmenteret nukleinsyre.
12. Fremgangsmåde ifølge krav 11, hvor det første, det andet eller begge transposomer er immobiliseret på faste bærere, eventuelt hvor den faste bærer er perler.

13. Fremgangsmåde ifølge et hvilket som helst af kravene 11-12, hvor det første transposon omfatter en første adaptor, og det andet transposon omfatter en anden adaptor, hvor den første og den anden adaptor er forskellige.

14. Fremgangsmåde ifølge et hvilket som helst af kravene 11-13, hvor den første og den anden adaptor omfatter en sekvens, der er valgt fra gruppen bestående af barcodes, primerbindingssekvenser, restriktionsendonukleasesteder og unikke molekylære indeks.

15. Fremgangsmåde ifølge et hvilket som helst af kravene 11-14, hvor det første transposaseenzym er valgt fra gruppen bestående af Mos-1, HyperMu™, Tn5, Ts-Tn5, Ts-Tn5059, Hermes, Tn7, eller det andet transposaseenzym er valgt fra gruppen bestående af Mos-1, HyperMu™, Tn5, Ts-Tn5, Ts-Tn5059, Hermes, Tn7.

DRAWINGS




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

700 ↗




Figure 7




Figure 8




Figure 9

1000




Figure 10

1100




Figure 11




Figure 12





Figure 14

Oligo Sequences Used for MuTsm

MM1141:

TGTTTCGCAATTATCGTGAAACGCTTCGCGTTTTTCGTGCGCGCTTCA

MM1138:

TCGGATGAAGCGGCGCACGAAAAACGCGAAAGGTTTCACGATAAATCGAAAAACA

MM1141	1	TGTTTCGCAATTATCGTGAAACGCTTCGCGTTTTTCGTGCGCGCGCTTCA	51
MM1138	56	TGTTTCGCGCAATTATCGTGAAACGCTTCGCGTTTTTCGTGCGCGCGCTTCA	6

Sequencing Primer (MuPCRTs):

CGTTTTTCGTGCGCGCTTCA

P7MUTS:

CAAGCAGAAGACGGCATACGAGATCGTTTTTCGTGCGCGCTTCA

P5MUTS:

AATGATACGGCGACCACCGAGATCTACACCGTTTTTCGTGCGCGCTTCA

Figure 16

Assessing Activity of MuTsm

The MuTsm was used to target a ~50kb bacteriophage genome. The reaction was done in TA buffer for 1 hr at 37°C.




Figure 17




Figure 18

Some Statistics of the Sequencing Run

total # of reads	30,071,951
# of reads passed eland alignment	16,775,955
# of unique reads	4,629,392
# of unique reads <2000bp	4,599,874
mean coverage	69.39X

Figure 19

Fragment Length Distribution

With a 2X150 MiSeq Run:
Mean Coverage = 4.6×10^5 reads $\times$ 300 bp / $4.6 \times 10^5 = 300$ X




Figure 20

Mu + Nextera Show a More Uniform Coverage Pattern




Figure 21

Figure 22A




Figure 22B




Figure 22C





Figure 22D






Figure 23





Figure 24

**Figure 25**




Figure 26

AT/GC Dropout-Picard




Figure 27




Figure 28